Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
9.01
+0.07 (0.78%)
Bozor ochiq: Aug 12, 2026, 1:17 PM EDT
8.94
0.00 (0.00%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Atara Biotherapeutics, Inc. Qo'shma Shtatlar va xalqaro miqyosda saraton va otoimmunitet kasalliklari bilan og'rigan bemorlar uchun transformativ terapiyalarni ishlab chiqish bilan shug'ullanadi. Uning asosiy mahsuloti Tab-cel (tabelecleucel) hisoblanadi, bu T-hujayrali immunoterapiya dasturi bo'lib, u transplantatsiyadan keyingi limfoproliferativ kasallikni, shuningdek, boshqa EBV bilan bog'liq kasalliklarni davolash uchun 3-bosqichli klinik sinovlarda. Kompaniya, shuningdek, B-hujayrali o'smalar va otoimmunitet kasalliklariga qarshi CD19ni nishonga olgan ATA3219, allogen CAR Tni ishlab chiqadi. Kompaniya Memorial Sloan Kettering Cancer Center va Queensland Medical Research Institute Kengashi bilan tadqiqot hamkorligi shartnomalariga ega. Atara Biotherapeutics, Inc. 2012-yilda tashkil etilgan va uning bosh qarorgohi Thousand Oaks, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Alex Chapman | Vice President of Corporate Communications & Investor Relations |
| Dr. Anhco Nguyen Ph.D. | President, CEO & Director |
| Mr. Jim Sesic | Senior Vice President of Regulatory Affairs |
| Mr. Kevin G. Sarney CPA | Interim Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-26 | 8-K | atra-20260622.htm |
| 2026-06-12 | S-8 | ea0294585-s8_atara.htm |
| 2026-06-12 | 8-K | ea0294561-8k_atara.htm |
| 2026-05-12 | 10-Q | atra-20260331.htm |
| 2026-05-07 | 8-K | atra-20260507.htm |
| 2026-05-01 | 8-K | atra-20260430.htm |
| 2026-04-24 | DEFA14A | atra-2026-defa14a.htm |
| 2026-04-24 | DEF 14A | atra-20260424.htm |
| 2026-03-23 | CORRESP | filename1.htm |
| 2026-03-17 | S-3 | d100379ds3.htm |